Sanofi (France)

Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

Isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd) has emerged as a standard of care for newly diagnosed multiple myeloma transplant-ineligible patients. A subcutaneous (SC) formulation of isatuximab delivered via an on-body injector (OBI) has been developed to facilitate...

Investigating patients’ experiences with dyspnea associated with warm autoimmune hemolytic anemia (wAIHA) and cognitive debriefing of the FACIT-Dyspnea 10-item short form: a qualitative patient interview study

Abstract Background Dyspnea is a prominent symptom in patients with warm autoimmune hemolytic anemia (wAIHA), yet its lived experience remain under-researched. Although clinically relevant, dyspnea is not routinely assessed in wAIHA trials, and no validated patient-reported outco...

Finetuning Foundation Models for Temporal Clinical Transcriptomics Data

BACKGROUND: Timeseries clinical transcriptomic datasets offer the opportunity to gain insights into the dynamics of disease mechanisms/treatment responses. However, their utility in uncovering temporal patterns is often limited by high noise levels and small sample sizes. Leverag...

A new standard for lyophilizer characterization, comparability and efficient technology transfers

This paper details the implementation of the ΔT and ΔP methodologies—recently introduced in the literature—for monitoring of mass flow during sublimation, demonstrating their application across multiple pharmaceutical companies. As a relatively new approach, this work is assessin...